+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vasopressin Antagonist Market - Global Forecast 2026-2032- Product Image
Vasopressin Antagonist Market - Global Forecast 2026-2032- Product Image
Sale

Vasopressin Antagonist Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6139149
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vasopressin Antagonist Market is projected to reach USD 1.49 Billion in 2026. It is expected to continue growing at a CAGR of 9.78%, reaching USD 2.61 Billion by 2032.

Vasopressin Antagonists: Executive Overview

Vasopressin antagonists are prescription medicines that modulate vasopressin signaling, with clinical use shaped by the indication, agent-specific labeling, route of administration, and local treatment guidelines. Their principal relevance is in conditions involving abnormal water handling, including selected forms of hyponatremia, while safety considerations require careful attention to serum sodium, fluid status, liver function where applicable, drug interactions, and treatment duration. Clinical adoption therefore depends on specialist oversight, diagnostic accuracy, hospital protocols, and access to monitoring.

Clinical Practice Is Shifting Toward Protocolized, Monitored Use

The landscape is being transformed by tighter integration between laboratory diagnostics, hospital formularies, and evidence-based treatment pathways. Clinicians increasingly distinguish the underlying cause of hyponatremia before selecting therapy, separating hypovolemic, euvolemic, and hypervolemic presentations and addressing reversible contributors such as medications or endocrine disorders. Regulatory restrictions, warnings about overly rapid correction of serum sodium, and the need for reassessment are encouraging controlled initiation, documentation, and follow-up rather than routine or unsupervised use.

Artificial Intelligence Supports Triage, Monitoring, and Evidence Review

Artificial intelligence can strengthen vasopressin-antagonist care by flagging abnormal sodium trends, identifying patients at risk of medication-related complications, and helping integrate laboratory results, diagnoses, medicines, and fluid-balance records. Predictive tools may assist clinicians in prioritizing review, but they should complement-not replace-clinical judgment, validated protocols, and direct assessment. Important safeguards include representative training data, explainable alerts, protection of patient information, prospective validation, and oversight of false positives and missed deterioration.

Regional Insights: Access and Monitoring Capacity Shape Utilization

North America generally emphasizes specialist prescribing, hospital protocols, and structured laboratory monitoring. Europe combines national guidance with country-specific reimbursement and regulatory processes, while the European Union supports cross-border scientific and pharmacovigilance coordination. Asia-Pacific presents varied access across Australia, China, India, Japan, and South Korea, with advanced tertiary-care capacity alongside uneven availability of specialist monitoring. Latin America, including Brazil and Mexico, is influenced by public-sector procurement, referral networks, and affordability. The Middle East, including GCC health systems, often benefits from concentrated tertiary-care infrastructure, whereas Africa faces wider variation in diagnostic access, supply continuity, and specialist coverage. Across all regions, safe use depends on timely electrolyte testing and appropriately trained clinicians.

Group Insights: Policy Alignment and Health-System Readiness Matter

ASEAN markets reflect diverse regulatory systems, hospital capabilities, and procurement arrangements, making regional harmonization valuable but incomplete. BRICS members span substantial differences in manufacturing capacity, public financing, clinical infrastructure, and access to nephrology and critical-care services. The European Union benefits from coordinated regulatory and safety frameworks while retaining national reimbursement decisions. G7 health systems generally have mature pharmacovigilance and laboratory networks, although prescribing criteria and coverage differ. GCC countries often concentrate advanced care in major urban centers. NATO members do not constitute a uniform healthcare market, but their varied preparedness, procurement, and hospital systems underscore the importance of resilient supply and standardized emergency protocols.

Country Insights: Regulatory Context and Care Pathways Differ

Australia combines established hospital governance with specialist-led prescribing and safety monitoring. Brazil and Mexico must account for public procurement, regional referral variation, and affordability. Canada and the United States rely on regulated labeling, hospital protocols, and access to laboratory follow-up, with coverage differing by jurisdiction and payer. China and India show substantial regional variation in tertiary-care access and diagnostic capacity. France, Germany, Italy, and Spain operate within European regulatory structures but retain distinct reimbursement, formulary, and prescribing pathways. Japan and South Korea have sophisticated clinical systems with country-specific approval and monitoring requirements. Russia’s access and supply environment is shaped by domestic regulatory and procurement conditions. The United Kingdom emphasizes national clinical guidance, formulary governance, and structured monitoring.

Leadership Priorities for Safer, More Consistent Use

Industry leaders should align medical, regulatory, market-access, and pharmacovigilance teams around indication-specific evidence and clear patient-selection criteria. They should support clinician education on differential diagnosis, sodium-correction limits, contraindications, interactions, and discontinuation or follow-up procedures. Health-system partnerships can improve laboratory turnaround, electronic alerting, and standardized order sets. Organizations should also maintain resilient supply planning, document real-world safety outcomes, and evaluate digital decision-support tools through transparent validation. Access strategies should reflect local reimbursement rules and infrastructure rather than assume that a single regional approach will work across all settings.

Methodology: Evidence-Led Synthesis of Clinical and System Factors

This executive summary uses the defined vasopressin-antagonist scope and synthesizes established clinical, regulatory, and health-system considerations from authoritative categories of evidence, including product labeling, treatment guidelines, peer-reviewed literature, pharmacovigilance principles, and public healthcare-policy materials. Findings are organized across global regions, economic and political groups, and the specified countries. No market estimates, market shares, forecasts, or company-specific claims are used. Because access and recommendations can change, country-level interpretation should be checked against current local approvals, formularies, and professional guidance.

Conclusion: Responsible Integration Depends on Monitoring and Context

Vasopressin antagonists occupy a clinically specialized role in managing selected disorders of water balance. Their value is determined less by medicine availability alone than by accurate diagnosis, appropriate patient selection, controlled sodium correction, laboratory capacity, and informed follow-up. Regional and country differences in regulation, reimbursement, and clinical infrastructure will continue to shape implementation. Leaders who combine evidence-based protocols, safety surveillance, workforce education, resilient access, and carefully governed digital tools will be best positioned to support consistent and responsible care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Vasopressin Antagonist Market, by Mechanism Of Action
7.1. Introduction
7.2. Non Selective V1a V2 Receptor
7.3. Selective V2 Receptor
8. Vasopressin Antagonist Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Vasopressin Antagonist Market, by Dosage Form
9.1. Introduction
9.2. Lyophilized Powder
9.3. Tablets
10. Vasopressin Antagonist Market, by Indication
10.1. Introduction
10.2. Congestive Heart Failure
10.2.1. Preserved Ejection Fraction
10.2.2. Reduced Ejection Fraction
10.3. Liver Cirrhosis
10.3.1. Compensated
10.3.2. Decompensated
10.4. Syndrome Of Inappropriate Antidiuretic Hormone Secretion
11. Vasopressin Antagonist Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Vasopressin Antagonist Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Vasopressin Antagonist Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Vasopressin Antagonist Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amgen Inc
16.2. Astellas Pharma
16.3. Astellas Pharma Inc
16.4. Bausch Health Companies Inc
16.5. Cumberland Pharmaceuticals Inc
16.6. Daiichi Sankyo Company Limited
16.7. Eisai Co Ltd
16.8. Ipsen Biopharmaceuticals
16.9. Kadmon Holdings Inc
16.10. Lundbeck A/S
16.11. Merck & Co Inc
16.12. Novartis AG
16.13. Otsuka Pharmaceutical Co Ltd
16.14. Pfizer Inc
16.15. Pharmacosmos A/S
16.16. Recordati S.p.A
16.17. Sanofi
16.18. Terrapeutics LLC
16.19. Teva Pharmaceutical Industries Ltd
16.20. Vifor Pharma Group
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Vasopressin Antagonist Market, Years Considered for the Study
FIGURE 2. Global Vasopressin Antagonist Market, Research Design
FIGURE 3. Global Vasopressin Antagonist Market, Research Framework
FIGURE 4. Global Vasopressin Antagonist Market, Data Triangulation
FIGURE 5. Global Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Vasopressin Antagonist Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 7. Global Vasopressin Antagonist Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Vasopressin Antagonist Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Vasopressin Antagonist Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Vasopressin Antagonist Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Vasopressin Antagonist Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Vasopressin Antagonist Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 13. Global Vasopressin Antagonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Vasopressin Antagonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Vasopressin Antagonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Vasopressin Antagonist Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Vasopressin Antagonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Vasopressin Antagonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Vasopressin Antagonist Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Vasopressin Antagonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Vasopressin Antagonist Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Vasopressin Antagonist Market Segmentation & Coverage
TABLE 2. Global Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 3. Global Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 4. Global Non Selective V1a V2 Receptor Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Non Selective V1a V2 Receptor Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Non Selective V1a V2 Receptor Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Selective V2 Receptor Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Selective V2 Receptor Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Selective V2 Receptor Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 11. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 18. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 25. Global Congestive Heart Failure Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Congestive Heart Failure Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Congestive Heart Failure Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Preserved Ejection Fraction Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Preserved Ejection Fraction Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Preserved Ejection Fraction Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Reduced Ejection Fraction Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Reduced Ejection Fraction Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Reduced Ejection Fraction Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Liver Cirrhosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Liver Cirrhosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Liver Cirrhosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Compensated Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Compensated Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Compensated Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Decompensated Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Decompensated Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Decompensated Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Syndrome Of Inappropriate Antidiuretic Hormone Secretion Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Syndrome Of Inappropriate Antidiuretic Hormone Secretion Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Syndrome Of Inappropriate Antidiuretic Hormone Secretion Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 47. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 65. North America Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. North America Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 67. North America Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 68. North America Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 69. North America Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. North America Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 71. North America Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 72. North America Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. Latin America Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Latin America Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 75. Latin America Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 76. Latin America Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 77. Latin America Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Latin America Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 79. Latin America Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 80. Latin America Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. Europe Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Europe Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 83. Europe Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 84. Europe Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 85. Europe Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. Europe Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 87. Europe Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 88. Europe Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 89. Middle East Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 91. Middle East Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 92. Middle East Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 93. Middle East Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 94. Middle East Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 95. Middle East Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 96. Middle East Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Africa Vasopressin Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Africa Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 99. Africa Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. Africa Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 101. Africa Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 102. Africa Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 103. Africa Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 104. Africa Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. Global Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. ASEAN Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 108. ASEAN Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. ASEAN Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 110. ASEAN Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 111. ASEAN Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 112. ASEAN Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 113. ASEAN Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. GCC Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. GCC Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 116. GCC Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 117. GCC Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 118. GCC Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 119. GCC Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 120. GCC Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 121. GCC Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. European Union Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. European Union Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 124. European Union Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 125. European Union Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 126. European Union Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. European Union Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 128. European Union Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 129. European Union Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. BRICS Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. BRICS Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 132. BRICS Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 133. BRICS Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 134. BRICS Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. BRICS Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 136. BRICS Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 137. BRICS Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. G7 Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. G7 Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 140. G7 Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. G7 Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 142. G7 Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 143. G7 Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 144. G7 Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 145. G7 Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. NATO Vasopressin Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. NATO Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 148. NATO Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. NATO Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 150. NATO Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. NATO Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 152. NATO Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 153. NATO Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Global Vasopressin Antagonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. United States Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 156. United States Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 157. United States Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. United States Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 159. United States Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. United States Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 161. United States Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 162. United States Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Canada Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 164. Canada Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 165. Canada Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 166. Canada Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 167. Canada Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. Canada Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 169. Canada Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 170. Canada Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. Mexico Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 172. Mexico Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 173. Mexico Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 174. Mexico Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 175. Mexico Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. Mexico Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 177. Mexico Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 178. Mexico Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. Brazil Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 180. Brazil Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 181. Brazil Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 182. Brazil Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 183. Brazil Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. Brazil Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 185. Brazil Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 186. Brazil Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. United Kingdom Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 188. United Kingdom Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 189. United Kingdom Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 190. United Kingdom Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 191. United Kingdom Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. United Kingdom Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 193. United Kingdom Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 194. United Kingdom Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. Germany Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 196. Germany Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 197. Germany Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 198. Germany Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 199. Germany Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. Germany Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 201. Germany Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 202. Germany Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. France Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 204. France Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 205. France Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. France Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 207. France Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. France Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 209. France Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 210. France Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 211. Russia Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 212. Russia Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 213. Russia Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 214. Russia Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 215. Russia Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 216. Russia Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 217. Russia Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 218. Russia Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. Italy Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 220. Italy Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 221. Italy Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. Italy Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 223. Italy Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. Italy Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 225. Italy Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 226. Italy Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. Spain Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 228. Spain Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 229. Spain Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 230. Spain Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 231. Spain Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 232. Spain Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 233. Spain Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 234. Spain Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 235. China Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 236. China Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 237. China Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 238. China Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 239. China Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. China Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 241. China Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 242. China Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. India Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 244. India Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 245. India Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 246. India Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 247. India Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. India Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 249. India Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 250. India Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Japan Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 252. Japan Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 253. Japan Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. Japan Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 255. Japan Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 256. Japan Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 257. Japan Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 258. Japan Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Australia Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 260. Australia Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 261. Australia Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 262. Australia Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 263. Australia Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 264. Australia Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 265. Australia Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 266. Australia Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 267. South Korea Vasopressin Antagonist Market Size, 2017-2032 (USD Million)
TABLE 268. South Korea Vasopressin Antagonist Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 269. South Korea Vasopressin Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 270. South Korea Vasopressin Antagonist Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 271. South Korea Vasopressin Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 272. South Korea Vasopressin Antagonist Market Size, by Congestive Heart Failure, 2017-2032 (USD Million)
TABLE 273. South Korea Vasopressin Antagonist Market Size, by Liver Cirrhosis, 2017-2032 (USD Million)
TABLE 274. South Korea Vasopressin Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. Global Vasopressin Antagonist Market Share, by Key Player, 2025
TABLE 276. Global Vasopressin Antagonist Market, Key Experts

Companies Mentioned

  • Amgen Inc
  • Astellas Pharma
  • Astellas Pharma Inc
  • Bausch Health Companies Inc
  • Cumberland Pharmaceuticals Inc
  • Daiichi Sankyo Company Limited
  • Eisai Co Ltd
  • Ipsen Biopharmaceuticals
  • Kadmon Holdings Inc
  • Lundbeck A/S
  • Merck & Co Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Pharmacosmos A/S
  • Recordati S.p.A
  • Sanofi
  • Terrapeutics LLC
  • Teva Pharmaceutical Industries Ltd
  • Vifor Pharma Group

Related Topics

Related Reports

Vasopressin for Vasoplegic Shock Market Outlook 2026-2034: Market Share, and Growth Analysis by Dosage Form, Route of Administration, End-User - Product Image

Vasopressin for Vasoplegic Shock Market Outlook 2026-2034: Market Share, and Growth Analysis by Dosage Form, Route of Administration, End-User

  • Report
  • 160 Pages
  • Global
From
Vasopressin Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Vasopressin Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Vasopressin Market Report 2026 - Product Image

Vasopressin Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Ascites Pipeline Analysis Report 2025 - Product Image

Ascites Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Vasopressin - Product Image

Vasopressin

  • Book
Copyright © 2002-2026 Research and Markets. All Rights Reserved.